OS Therapies (NYSEAMERICAN:OSTX) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of OS Therapies (NYSEAMERICAN:OSTX) from a strong sell rating to a hold rating in a research note released on Thursday,Zacks.com reports.

A number of other equities analysts also recently weighed in on the stock. Lake Street Capital decreased their target price on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. D. Boral Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of OS Therapies in a research note on Thursday, April 30th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $16.50.

OS Therapies Price Performance

OSTX stock opened at $1.78 on Thursday. OS Therapies has a 1 year low of $1.15 and a 1 year high of $2.57. The company has a market cap of $79.28 million, a P/E ratio of -1.65 and a beta of -0.95. The firm has a 50-day moving average of $1.61 and a 200 day moving average of $1.55.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings results on Monday, May 18th. The company reported ($0.27) earnings per share (EPS) for the quarter. On average, equities research analysts expect that OS Therapies will post 0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OS Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in the business. CM Management LLC increased its stake in shares of OS Therapies by 6.7% during the third quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $784,000 after purchasing an additional 25,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of OS Therapies by 31.1% during the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock valued at $344,000 after buying an additional 58,350 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of OS Therapies during the third quarter valued at approximately $183,000. Two Sigma Investments LP purchased a new stake in shares of OS Therapies during the third quarter valued at approximately $169,000. Finally, Virtu Financial LLC grew its holdings in shares of OS Therapies by 252.0% during the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after buying an additional 54,269 shares during the last quarter.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.